SA Medicine

SA Medicine133 連載「化学療法薬の有害事象:第1回」著者:大参亜紀


1.Kopecny L, Palm CA, Skorupski KA, Delgado M, Rebhun RB. Risk factors associated with progressive increases in serum creatinine concentrations in cats with cancer receiving doxorubicin. J Vet Intern Med. 2020 Sep;34(5):2048-2055.

2.Blake MK, Carr BJ, Mauldin GE. Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012. Can Vet J. 2016 Feb;57(2):176-82.

3.Moore AS, Frimberger AE, Chan CM. Dosage escalation of intravenous cyclophosphamide in cats with cancer. Vet J. 2018 Dec;242:39-43.

4.Knapp DW, Richardson RC, DeNicola DB, Long GG, Blevins WE. Cisplatin toxicity in cats. J Vet Intern Med. 1987 Jan-Mar;1(1):29-35.

5.Gagnon J, Dervisis NG, Kitchell BE. Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment. J Feline Med Surg. 2012 Aug;14(8):560-5.

6.Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group – Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 2004 Dec;2(4):195-213.

7.Veterinary cooperative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016 Dec;14(4):417-446.

8.LeBlanc AK, Atherton M, Bentley RT, Boudreau CE, Burton JH, Curran KM, Dow S, Giuffrida MA, Kellihan HB, Mason NJ, Oblak M, Selmic LE, Selting KA, Singh A, Tjostheim S, Vail DM, Weishaar KM, Berger EP, Rossmeisl JH, Mazcko C. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021 Jan 11. doi: 10.1111/vco.12677. Epub ahead of print.

Google Chromeなどの最新のブラウザをダウンロードし当サイトをご利用ください。